SESSION POSTERS

How are human stem cells transforming the future of neurological disease research and treatment? Dr. Sally Temple, a world-renowned pioneer who has opened new frontiers in neural stem cell research, takes the BIX stage to explore the answer.

In this keynote session, discover how human stem cell technologies are reshaping the way we understand and treat neurological diseases — from disease modeling to cell therapy.

Drawing on decades of work translating fundamental discoveries into potential therapies, Dr. Temple will share insights into the emerging strategies and possibilities that could accelerate the development of new treatments for neurological disorders.

What ultimately determines whether a biopharma deal succeeds at the negotiating table?

In this keynote session, Stuart M. Cable, who has advised on some of the world’s most prominent biopharma M&A transactions — including Pfizer’s $43 billion acquisition of Seagen, Sanofi’s $9.5 billion acquisition of Blueprint Medicines, and Bristol Myers Squibb’s $13.1 billion acquisition of MyoKardia — takes us inside the dynamics that drive deals in the global market.

Explore the key forces shaping biopharma M&A today, from Big Pharma and mid-sized pharmaceutical companies acquiring innovative biotech businesses to deal size and structure, executive compensation, and regulatory risk.

At BIX, discover the numbers, terms, and strategic thinking behind the deals transforming the biopharma landscape.

What if people could control devices and communicate with others using only brain signals?

In this Session, meet Dion M. Kelly, Ph.D., Co-Founder and CEO of Possibility Neurotechnologies, a company developing brain-computer interface technology for people with severe physical disabilities.

Canada-based Possibility Neurotechnologies has developed Think2Switch™, as the world’s first commercial BCI platform that enables users to communicate and control digital devices through brain activity alone. The platform is designed to help people with severe physical disabilities and children communicate, learn, play, and take part in creative activities in everyday settings. Since its launch in 2026, it has reached users in 17 countries and is currently being introduced across more than 30 hospitals, rehabilitation centers, schools, and therapy institutions.

Hear directly about the challenges and lessons involved in taking BCI technology beyond the lab and into real-world use. The session will explore how neuroscience research can change everyday life — and what it takes to turn breakthrough technology into practical solutions for users.